Clear Cell Renal Cell Carcinoma Clinical Trials in Atlanta, Georgia

4 studies are recruiting for clear cell renal cell carcinoma in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

    This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attac…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Grady Health System, Atlanta, Georgia
    Locations
    425 in total
    Run by
    Alliance for Clinical Trials in Oncology

    See if you can join NCT06661720 on ClinicalTrials.gov

  2. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

    The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Atlanta, Georgia
    Locations
    25 in total
    Run by
    Arcus Biosciences, Inc.

    See if you can join NCT05536141 on ClinicalTrials.gov

  3. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Xencor Investigative Site, Atlanta, Georgia
    Locations
    26 in total
    Run by
    Xencor, Inc.

    See if you can join NCT05433142 on ClinicalTrials.gov

  4. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory - Winship Cancer Institute, Atlanta, Georgia
    Locations
    27 in total
    Run by
    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.